Key points are not available for this paper at this time.
Ipilimumab, an immune checkpoint inhibitor, is approved for the treatment of advanced melanoma. Its potential activity in keratinocytic cancers, however, is not well known. We present a case of a man in his 60s with advanced basal cell carcinoma (BCC) that regressed after incidental exposure to ipilimumab to treat the patient's concurrent metastatic melanoma.
Mohan et al. (Fri,) studied this question.